Pinto A J, Morahan P S, Brinton M A
Department of Microbiology and Immunology, Medical College of Pennsylvania, Philadelphia 19129.
Int J Immunopharmacol. 1988;10(3):197-209. doi: 10.1016/0192-0561(88)90050-1.
Several immunomodulators were compared for immunomodulatory and antiviral activity in B6C3F1 female mice. Our results demonstrate that murine recombinant gamma interferon (rIFN-G), human recombinant alpha A/D interferon (rIFN-A), ampligen (a polyribonucleotide) and CL246,738 modulate nonspecific immunity and are effective antiviral agents in vivo. Administration of each of these agents 1 day before cell harvest induced high levels of splenic natural killer (NK) cell activity against YAC-1 target cells. rIFN-G was also a potent activator of peritoneal macrophages (M phi), as evidenced by high levels of antitumor activity and changes in ectoenzyme phenotype that is characteristic of tumoricidal M phi. rIFN-A, ampligen and CL246,738 induced moderate to low levels of M phi activation by these criteria. In vivo protection experiments showed that repeated therapeutic treatment with rIFN-A protected mice against i.p. infection with Venezuelan equine encephalitis (an alpha togavirus, VEE), Banzi (a flavivirus) and herpes simplex virus type 2 (HSV-2). Similar treatment with rIFN-G was effective against VEE and HSV-2, but ineffective against Banzi virus. A single prophylactic i.p. dose of ampligen 1 day before virus challenge was very effective against Banzi virus, moderately effective against HSV-2, and ineffective against VEE and Caraparu (a bunyavirus) infection. A single prophylactic oral dose of CL246,738 provided almost complete protection of mice against VEE, Banzi, and HSV-2, and also increased the mean survival time for Caraparu infected mice. Collectively, these results indicate that rIFN-A, r-IFN-G, ampligen and CL246,738 may be useful in prophylactic or early therapeutic treatment of several serious virus infections. Since these agents stimulate NK cells and M phi, their antiviral activity may result, in part, from the alterations they induce in the natural immune system.
在B6C3F1雌性小鼠中比较了几种免疫调节剂的免疫调节和抗病毒活性。我们的结果表明,鼠重组γ干扰素(rIFN-G)、人重组αA/D干扰素(rIFN-A)、扩增素(一种多聚核苷酸)和CL246,738可调节非特异性免疫,并且在体内是有效的抗病毒剂。在细胞收获前1天给予这些药剂中的每一种,均可诱导针对YAC-1靶细胞的高水平脾自然杀伤(NK)细胞活性。rIFN-G也是腹膜巨噬细胞(M phi)的有效激活剂,高水平的抗肿瘤活性以及具有杀肿瘤M phi特征的外切酶表型变化证明了这一点。根据这些标准,rIFN-A、扩增素和CL246,738诱导M phi激活的水平为中度至低度。体内保护实验表明,用rIFN-A重复进行治疗性处理可保护小鼠免受委内瑞拉马脑炎(一种α披膜病毒,VEE)、班齐病毒(一种黄病毒)和2型单纯疱疹病毒(HSV-2)的腹腔感染。用rIFN-G进行类似处理对VEE和HSV-2有效,但对班齐病毒无效。在病毒攻击前1天腹腔内单次预防性给予扩增素对班齐病毒非常有效,对HSV-2中度有效,对VEE和卡拉帕鲁病毒(一种布尼亚病毒)感染无效。口服单次预防性给予CL246,738几乎可完全保护小鼠免受VEE、班齐病毒和HSV-2感染,并且还延长了卡拉帕鲁病毒感染小鼠的平均存活时间。总体而言,这些结果表明,rIFN-A、r-IFN-G、扩增素和CL246,738可能对几种严重病毒感染的预防性或早期治疗有用。由于这些药剂刺激NK细胞和M phi,它们的抗病毒活性可能部分源于它们在天然免疫系统中诱导的改变。